{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:06:55Z","timestamp":1790856415466,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.clon.2023.08.006","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T03:14:22Z","timestamp":1693451662000},"page":"736-743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit?"],"prefix":"10.1016","volume":"35","author":[{"given":"S.K.","family":"Nagpal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Khabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2023.08.006_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"Hellman","year":"1995","journal-title":"Oligometastases J Clin Oncol"},{"key":"10.1016\/j.clon.2023.08.006_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.e11512","article-title":"Incidence and implications of oligometastatic breast cancer","volume":"30","author":"Jain","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2023.08.006_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102462","article-title":"Oligometastatic breast cancer: dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?","volume":"110","author":"Miglietta","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clon.2023.08.006_bib4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2023.08.006_bib5","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1158\/0008-5472.CAN-09-0099","article-title":"Breast cancer metastasis: challenges and opportunities","volume":"69","author":"Lu","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.clon.2023.08.006_bib6","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2023.08.006_bib7","series-title":"CORE \u2013 standard of care +\/- stereotactic body radiotherapy for oligometastases - primary results","author":"Khoo","year":"2023"},{"key":"10.1016\/j.clon.2023.08.006_bib8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(20)30537-4","article-title":"Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study","volume":"22","author":"Chalkidou","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2023.08.006_bib9","series-title":"Clinical Commissioning Policy Stereotactic ablative radiotherapy (SABR) for patients with metachronous extracranial oligometastatic cancer (all ages)","year":"2023"},{"key":"10.1016\/j.clon.2023.08.006_bib10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","article-title":"NRG-BR002: A phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557)","volume":"40","author":"Chmura","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2023.08.006_bib11","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.cllc.2014.04.003","article-title":"An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer","volume":"15","author":"Ashworth","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.clon.2023.08.006_bib12","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-15-0822","article-title":"New strategies in stereotactic radiotherapy for oligometastases","volume":"21","author":"Palma","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2023.08.006_bib13","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/annonc\/mdu370","article-title":"Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients","volume":"25","author":"Collen","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2023.08.006_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.breast.2013.10.007","article-title":"Primary and secondary distant metastatic breast cancer: two sides of the same coin","volume":"23","author":"G\u00fcth","year":"2014","journal-title":"Breast"},{"key":"10.1016\/j.clon.2023.08.006_bib15","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdq220","article-title":"Survival differences among women with de novo stage IV and relapsed breast cancer","volume":"21","author":"Dawood","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clon.2023.08.006_bib16","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3390\/curroncol30020108","article-title":"Management of oligometastatic breast cancer: an expert committee\u2019s opinion","volume":"30","author":"Leblanc","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clon.2023.08.006_bib17","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2023.08.006_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2023.08.006_bib19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00066-022-01938-x","article-title":"Oligometastasis in breast cancer \u2013 current status and treatment options from a radiation oncology perspective","volume":"198","author":"Piroth","year":"2022","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.clon.2023.08.006_bib20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.radonc.2021.09.031","article-title":"Stereotactic body radiotherapy to treat breast cancer oligometastases: a systematic review with meta-analysis: SBRT for breast cancer oligometastases","volume":"164","author":"Viani","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2023.08.006_bib21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.breast.2022.12.035","article-title":"Systemic treatment with or without ablative therapies in oligometastatic breast cancer: a single institution analysis of patient outcomes","volume":"67","author":"Glemarec","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.clon.2023.08.006_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195149","article-title":"Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: a multi-institutional pooled analysis","volume":"13","author":"Hong","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clon.2023.08.006_bib23","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/bjc.1998.52","article-title":"Clinical course and prognostic factors following bone recurrence from breast cancer","volume":"77","author":"Coleman","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clon.2023.08.006_bib24","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1470-2045(21)00196-0","article-title":"Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2\/3 trial","volume":"22","author":"Sahgal","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2023.08.006_bib25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2020.01.016","article-title":"Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008\u20132016","volume":"129","author":"Deluche","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2023.08.006_bib26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10549-023-06880-9","article-title":"Clinical and pathological characterization of 158 consecutive and unselected oligometastatic breast cancers in a single institution","volume":"198","author":"Lacaze","year":"2023","journal-title":"Breast Cancer Res Treat"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655523002996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655523002996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:53:10Z","timestamp":1760543590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655523002996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0936655523002996"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2023.08.006","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit?","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2023.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}